Stem cell therapy brings good news for patients with heart failure
Patients with heart failure may benefit of the emerging stem cell therapy according to the recently published results of the RIMECARD Trial.
Improvements in the heart's pumping ability of the patients, in their capacity to perform the normal daily activities and in general, in the quality of their life.
Stem cell therapy a new approach for intractable epileptic seizures
Existing anti-epileptic drugs (AED) have limited efficiency in approximately 30 % of patients, experiencing intractable epileptic seizures, so called drug-resistant epilepsy.
Stem cell therapy may be a safe and promising new therapeutic approach for these patients, according to the results of a recently published clinical study.
Gene therapy for Wiskott-Aldrich Syndrome cautiously encouraging first results
Safety on short and long term related with manipulation of the genetic information is a major concern related with this new approach, as alternative to blood forming transplant from a healthy donor.
The importance of this aspect has been highlighted once more by the follow up of the first clinical trial evaluating the gene therapy for Wiskott-Aldrich Syndrome.
STEM CELLS FOR HYPOXIC BRAIN DAMAGE AN INNOVATIVE APPROACH
The possibility of using umbilical cord blood stem cell as therapy for newborns, with severe brain hypoxic lessions was assessed by a first small pilot study.
Babies who suffered brain damage due to shortage in brain oxygenation and /or blood supply previous, during or soon after the birth (hypoxic-ischemic encephalopathy) were infused with their own cord blood.
A new potential treatment addressing neurological challenges of congenital hydrocephalus
Based on preclinical study results corroborated with previous clinical studies applying umbilical cord blood as stem cell therapy for acquired pediatric neurological diseases, a medical team from Duke University Hospital lead by prof. dr. Joanne Kurtzberg has initiated a phase I clinical study.
During this clinical trial, first-in-man proof-of-concept safety study, 76 patients with congenital hydrocephalus were treated with 143 autologous CB infusions between October 2006 and August 2014.
News from stem cell research field about cerebral palsy
Based on the particular biological features of stem cells, the preclinical (laboratory) encouraging outcomes and the results of first clinical trials on safety and feasibility in acquired brain injury, cord blood is prefiguring as a very promising source for stem cell based therapy in pediatric neurology.
The results of an advanced clinical study were published in "Blood" journal in 2015. They represent the outcome of phase II clinical trial1 "designed to assess the efficacy of a single intravenous infusion of autologous cord blood in young children with spastic cerebral palsy"
Cordin an innovating stem cell treatment for patients with severe aplastic anemia
Gamida Cell has announced that first patient was transplanted in this Phase 1/2 Study of CordInTM for Severe Aplastic Anemia and Hypoplastic MDS , according to a press release issued last month.
CordIn™ is one of the innovative stem cell treatment produced by Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases.
Promising results for children with autism
Results from a Phase I clinical trial, evaluating the safety and feasibility of intravenous infusion of own umbilical cord blood were published this year. In this small, early stage clinical trial, 25 children ages 2 to 5, (median age 4,6 years) with a confirmed diagnosis of autism spectrum disorder (ASD), had undergone the new experimental treatment proposed by the scientists at Duke Health.
All the children enrolled in the clinical trial had available their own umbilical cord blood stored in family banks, according with parents decision to collect the blood at their birth.
Stem Cell Educator – New Hopes For Patients With Diabetes Mellitus
New hopes are coming from a recently published article in "Stem Cells Translational Medicine" for patients with Diabetes mellitus type 1 (T1D) and type 2 (T2D).
The 4 year follow-up studies demonstrated the long term safety and clinical efficacy of stem cell educator therapy for the treatment of T1D and T2D.
But let's get more deep into understanding this Stem Cell Educator, how is it work and who could benefit of it.
Soon more medical news on stem cells.